Brensocatib Patent Expiration
Brensocatib was first introduced by Insmed Inc
Brensocatib Patents
Given below is the list of patents protecting Brensocatib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Brinsupri | US12059424 | Pharmaceutical Compositions Comprising (2S)-N-{(1S)-1-Cyano-2-[4-(3-Methyl-2-Oxo-2,3-Dihydro-1,3-Benzoxazol-5-Yl)Phenyl]Ethyl}-1,4-Oxazepane-2-Carboxamide | Feb 21, 2040 | Insmed Inc |
| Brinsupri | US12201638 | Pharmaceutical Compositions Comprising (2S)-N-{(1S)-1-Cyano-2-[4-(3-Methyl-2-Oxo-2,3-Dihydro-1,3-Benzoxazol-5-Yl)Phenyl]Ethyl}-1,4-Oxazepane-2-Carboxamide | Mar 01, 2039 | Insmed Inc |
| Brinsupri | US9522894 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Mar 12, 2035 | Insmed Inc |
| Brinsupri | US10287258 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US10669245 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US11655221 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US11655222 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US11655223 | Certain (2S)-N-[(1 S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US11655224 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US11673871 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US11773069 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US11814359 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US12054465 | Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
| Brinsupri | US9815805 | Certain (25)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides As Dipeptidyl Peptidase 1 Inhibitors | Jan 21, 2035 | Insmed Inc |
Brensocatib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Brensocatib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) | Insmed Incorporated | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2 |